000285056 001__ 285056
000285056 005__ 20260209153611.0
000285056 0247_ $$2doi$$a10.1002/alz.71192
000285056 0247_ $$2pmid$$apmid:41657128
000285056 0247_ $$2ISSN$$a1552-5260
000285056 0247_ $$2ISSN$$a1552-5279
000285056 037__ $$aDZNE-2026-00180
000285056 041__ $$aEnglish
000285056 082__ $$a610
000285056 1001_ $$00000-0002-1671-6850$$avan der Veere, Pieter J$$b0
000285056 245__ $$aRevising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays.
000285056 260__ $$aHoboken, NJ$$bWiley$$c2026
000285056 3367_ $$2DRIVER$$aarticle
000285056 3367_ $$2DataCite$$aOutput Types/Journal article
000285056 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770647723_24271
000285056 3367_ $$2BibTeX$$aARTICLE
000285056 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285056 3367_ $$00$$2EndNote$$aJournal Article
000285056 520__ $$aAutomated cerebrospinal fluid (CSF) biomarker assays have largely replaced manual immunoassays for measuring amyloid pathology in CSF. We refitted and validated the ABIDE model, predicting progression from mild cognitive impairment (MCI) to dementia, with CSF measurements from the automated Elecsys platform.We included 2413 MCI participants (998 [41%] amyloid-positive) from seven observational cohorts. Elecsys was used in 958 (40%) participants. The parameters of the previous ABIDE Cox model were re-estimated. Model discrimination and calibration were evaluated with leave-one-cohort-out cross-validation.During follow-up, 1034 (42%; 585 [58%] amyloid-positive) participants developed dementia. Discrimination was good with Harrell's C of 0.70 (95% confidence interval [CI]: 0.66-0.73). Calibration was good in the total population and amyloid-positive subgroup, with substantial predicted progression risks for all amyloid-positive participants.We refitted the ABIDE model, predicting MCI to dementia progression, with automated CSF measurements. The model was well calibrated in amyloid-positive patients and may support clinical discussions regarding ATTs.
000285056 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285056 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285056 650_7 $$2Other$$aAlzheimer's disease
000285056 650_7 $$2Other$$aautomated cerebrospinal fluid assays
000285056 650_7 $$2Other$$acerebrospinal fluid
000285056 650_7 $$2Other$$adementia
000285056 650_7 $$2Other$$amild cognitive dementia
000285056 650_7 $$2Other$$aprediction
000285056 650_7 $$2NLM Chemicals$$aBiomarkers
000285056 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000285056 650_2 $$2MeSH$$aHumans
000285056 650_2 $$2MeSH$$aCognitive Dysfunction: cerebrospinal fluid
000285056 650_2 $$2MeSH$$aCognitive Dysfunction: diagnosis
000285056 650_2 $$2MeSH$$aDementia: cerebrospinal fluid
000285056 650_2 $$2MeSH$$aDementia: diagnosis
000285056 650_2 $$2MeSH$$aMale
000285056 650_2 $$2MeSH$$aFemale
000285056 650_2 $$2MeSH$$aAged
000285056 650_2 $$2MeSH$$aDisease Progression
000285056 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000285056 650_2 $$2MeSH$$aAmyloid beta-Peptides: cerebrospinal fluid
000285056 650_2 $$2MeSH$$aCohort Studies
000285056 650_2 $$2MeSH$$aAged, 80 and over
000285056 7001_ $$avan Harten, Argonde C$$b1
000285056 7001_ $$avan Maurik, Ingrid S$$b2
000285056 7001_ $$aTeunissen, Charlotte E$$b3
000285056 7001_ $$aBarkhof, Frederik$$b4
000285056 7001_ $$aVos, Stephanie J B$$b5
000285056 7001_ $$aFroelich, Lutz$$b6
000285056 7001_ $$aKornhuber, Johannes$$b7
000285056 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b8$$udzne
000285056 7001_ $$0P:(DE-2719)2000015$$aMaier, Wolfgang$$b9
000285056 7001_ $$0P:(DE-2719)2811024$$aPeters, Oliver$$b10$$udzne
000285056 7001_ $$aRüther, Eckart$$b11
000285056 7001_ $$aFrisoni, Giovanni B$$b12
000285056 7001_ $$aSpiru, Luiza$$b13
000285056 7001_ $$aFreund-Levi, Yvonne$$b14
000285056 7001_ $$aWallin, Åsa K$$b15
000285056 7001_ $$aHampel, Harald$$b16
000285056 7001_ $$aTsolaki, Magda$$b17
000285056 7001_ $$aKłoszewska, Iwona$$b18
000285056 7001_ $$aMecocci, Patrizia$$b19
000285056 7001_ $$aVellas, Bruno$$b20
000285056 7001_ $$aLovestone, Simon$$b21
000285056 7001_ $$aGalluzzi, Samantha$$b22
000285056 7001_ $$aHerukka, Sanna-Kaisa$$b23
000285056 7001_ $$aSantana, Isabel$$b24
000285056 7001_ $$aBaldeiras, I.$$b25
000285056 7001_ $$ade Mendonca, Alexandre$$b26
000285056 7001_ $$aSilva, Dina$$b27
000285056 7001_ $$aChetelat, Gael$$b28
000285056 7001_ $$aPoisnel, Géraldine$$b29
000285056 7001_ $$aVisser, Pieter Jelle$$b30
000285056 7001_ $$aJohnson, Sterling C$$b31
000285056 7001_ $$aStormrud, Erik$$b32
000285056 7001_ $$aHansson, Oskar$$b33
000285056 7001_ $$aPalmqvist, Sebastian$$b34
000285056 7001_ $$aPiñol-Ripoll, Gerard$$b35
000285056 7001_ $$aInitiative, Alzheimer's Disease Neuroimaging$$b36$$eCollaboration Author
000285056 7001_ $$aBerkhof, Johannes$$b37
000285056 7001_ $$avan der Flier, Wiesje M$$b38
000285056 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.71192$$gVol. 22, no. 2, p. e71192$$n2$$pe71192$$tAlzheimer's and dementia$$v22$$x1552-5260$$y2026
000285056 8564_ $$uhttps://pub.dzne.de/record/285056/files/DZNE-2026-00180.pdf$$yRestricted
000285056 8564_ $$uhttps://pub.dzne.de/record/285056/files/DZNE-2026-00180.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285056 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000285056 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000015$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000285056 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811024$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000285056 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285056 9141_ $$y2026
000285056 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-11-11$$wger
000285056 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-11
000285056 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-11
000285056 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-11
000285056 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-11
000285056 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-11
000285056 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-11
000285056 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-11
000285056 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-11
000285056 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-11-11
000285056 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-11-11
000285056 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x0
000285056 9201_ $$0I:(DE-2719)1011201$$kAG Wagner$$lNeuropsychology$$x1
000285056 9201_ $$0I:(DE-2719)5000000$$kAG Peters$$lBiomarker-Assisted Early Detection of Dementias$$x2
000285056 980__ $$ajournal
000285056 980__ $$aEDITORS
000285056 980__ $$aVDBINPRINT
000285056 980__ $$aI:(DE-2719)1410006
000285056 980__ $$aI:(DE-2719)1011201
000285056 980__ $$aI:(DE-2719)5000000
000285056 980__ $$aUNRESTRICTED